Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 1;27(10):e825-e826.
doi: 10.1093/oncolo/oyac170.

Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin"

Saskia Ingen-Housz-Oro  1   2 , Constance Thibault  3 , Pierre Sohier  4 , Nicolas Dupin  5
Affiliations
Editorial

Regarding "Management of Dermatologic Events Associated with the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin"

Saskia Ingen-Housz-Oro et al. Oncologist. .

Abstract

This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clinical aspect in a 75-year-old man: erythematous plaques with blisters on the inguinal folds (A), central epidermal sheet detachment on the axillary folds (B), and the elbows (C).
See this image and copyright information in PMC

Comment in

  • In Reply.
    Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Lacouture ME, et al. Oncologist. 2022 Oct 1;27(10):e827-e828. doi: 10.1093/oncolo/oyac171. Oncologist. 2022. PMID: 36036599 Free PMC article.

Comment on

References

    1. Lacouture ME, Patel AB, Rosenberg JE, et al. . Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 2022;27(3):e223-e232. 10.1093/oncolo/oyac001. - DOI - PMC - PubMed
    1. Powles T, Rosenberg JE, Sonpavde GP, et al. . Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125-1135. 10.1056/NEJMoa2035807. - DOI - PMC - PubMed
    1. Keerty D, Graham L, Haynes E, et al. . Flexural exanthema from enfortumab vedotin. Cureus 2020;12(5):e8102. 10.7759/cureus.8102. - DOI - PMC - PubMed
    1. Enescu CD, Artz C, Axelson A.. Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma. JAAD Case Rep 2022;21:140-143. 10.1016/j.jdcr.2022.01.005. - DOI - PMC - PubMed
    1. Francis A, Jimenez A, Sundaresan S, et al. . A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis. JAAD Case Rep 2021;7:57-59. 10.1016/j.jdcr.2020.10.020. - DOI - PMC - PubMed